Compare Genuine Parts Company (GPC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Incyte Corporation — how do they compare? Genuine Parts Company trades at $127.02 (market cap $17.67B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and Genuine Parts Company pays a 3.32% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Incyte Corporation for 33 Days on average.
| GPC | INCY | |
|---|---|---|
Market Cap | $17.67B | $22.85B |
Volume | 1,079,458 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $129.93 |
52-Week Low | $92.47 | $83.80 |
Typical Hold Time | 75 Days | 33 Days |
Enterprise Value | $23.76B | $18.35B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 2.2% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss, while profitability metrics like net income margin remain thin at 0.13%. The company's planned separation into automotive and industrial units by Q1 2027 is a key catalyst, supported by steady revenue growth to $24.3 billion in 2025.
The outlook is cautiously optimistic, with upside potential from the corporate split and dividend stability, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though execution risks and economic sensitivity warrant monitoring.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
